LOTTE BIOLOGICS, a contract development and manufacturing organisation (CDMO), has signed a Memorandum of Understanding (MOU) with AbTis, a specialist in antibody-drug conjugates (ADCs), to co-develop next-generation ADC technologies. The companies plan to combine AbTis’s AbClick® linker platform with LOTTE
PCI Pharma Services, a global contract development and manufacturing organisation (CDMO), has announced a new strategic investment to accelerate its growth and service expansion. The investment is co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from
Cellular Origins, a TTP company specialising in robotic manufacturing for cell and gene therapies (CGTs), has joined forces with CGT Catapult and Resolution Therapeutics to launch a new consortium project backed by a £1 million Smart Grant from Innovate UK.
I Peace, Inc., a GMP-compliant CDMO specialising in induced pluripotent stem cells (iPSCs), has entered into a collaboration with US-based Vita Therapeutics to co-develop universal iPS cell lines intended for use in allogeneic cell transplantation therapies. The project will utilise
Flamma, a global contract development and manufacturing organisation (CDMO), has announced the grand opening of a new current Good Manufacturing Practice (cGMP) facility in Dalian, China. The plant will enhance the company’s capacity to produce and commercialise small molecule active
Hongene Biotech Corporation, a contract development and manufacturing organisation (CDMO) focused on nucleic acid therapeutics, has played a central role in progressing DNV001, a novel GalNAc-conjugated siRNA therapy developed by Hangzhou Dingle Xinwei Biotechnology. The investigational new drug (IND) application
Myrtelle Inc. has commenced commercial-stage manufacturing for its investigational gene therapy product, MYR-101, developed for the treatment of Canavan disease. The initiative marks a key milestone in the company’s journey toward market readiness and expanded patient access. The manufacturing programme
GC Cell has announced a CDMO agreement with Dewcell, a Korean biotech firm developing stem cell-derived artificial platelets. The partnership will focus on the production and clinical readiness of Dewcell’s lead candidate, DCB-101 (en-aPLT), aimed at addressing chronic blood supply
Aenova has expanded its advanced technology offering with the introduction of a hot melt extrusion (HME) platform at its Regensburg, Germany site. The platform enables the production of amorphous solid dispersions (ASDs) for active pharmaceutical ingredients (APIs) up to Occupational
Alvotech, a global biotech company focused on biosimilars, has announced the acquisition of Switzerland-based Ivers-Lee Group, a specialist in assembly and packaging for the pharmaceutical industry. While Ivers-Lee will remain a separate legal entity, it will be integrated into Alvotech’s
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
